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Background: Insulin-like growth factor binding protein-2 (IGFBP-2) regulates the bioavailability, transportation, and
localization of insulin-like growth factor-I (IGF-I), an effective neuroprotectant in animal stroke models especially
when administered intranasally. Therefore, determining IGFBP-2′s endogenous distribution in the normal and ischemic
brain is essential in maximizing the neuroprotective potential of the intranasal IGF-I treatment approach. However,
current data on IGFBP-2 is limited to mRNA and in situ hybridization studies. The purpose of this study was to determine
if there are any changes in IGFBP-2 protein levels and distribution in ischemic brain and also to determine if IGFBPs play a
role in the transportation of intranasally administered IGF-I into the brain.
Results: Using an in vitro approach, we show that ischemia causes changes in the distribution of IGFBP-2 in primary
cortical neurons and astrocytes. In addition, we show using the transient middle cerebral artery occlusion (MCAO)
model in mice that there is a significant increase in IGFBP-2 levels in the stroke penumbra and core after 72 h. This
correlated with an overall increase in IGF-I after stroke, with the highest levels of IGF-I in the stroke core after 72 h.
Brain sections from stroke mice indicate that neurons and astrocytes located in the penumbra both have increased
expression of IGFBP-2, however, IGFBP-2 was not detected in microglia. We used binding competition studies to
show that intranasally administered exogenous IGF-I uptake into the brain is not receptor mediated and is likely
facilitated by IGFBPs.
Conclusions: The change in protein levels indicates that IGFBP-2 plays an IGF-I-dependent and -independent role in
the brain’s acute (neuroprotection) and chronic (tissue remodeling) response to hypoxic-ischemic injury. Competition
studies indicate that IGFBPs may have a role in rapid transportation of exogenous IGF-I from the nasal tissue to the site
of injury.
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Intranasal administrationBackground
Stroke is among the leading causes of neurological dis-
ability and has a devastating emotional and financial
burden on stroke survivors and their families [1]. The
only treatment currently available is thrombolysis with
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reproduction in any medium, provided the orlimited time window for treatment (<4.5 h) and the rigor-
ous inclusion criteria, less then 5% of stroke patients are
eligible for tPA treatment [2]. Unfortunately, there are no
other efficient therapies to ameliorate the resulting neuro-
degeneration caused be cerebral ischemia. Recent studies
have shown that intranasal administration of insulin-like
growth factor-I (IGF-I) is neuroprotective in animal
stroke models [3-5]. Other administration methods that
deliver drugs systemically depend on the breakdown of
the blood–brain barrier (BBB), however, this is not a
predictable event in the ischemic brain [6,7]. Therefore,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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administer intravascular drugs as neurological therapeu-
tics. In contrast, intranasal administration circumvents the
BBB and is capable of directly transporting drugs [8] and
even cells [9] into the central nervous system (CNS)
via transcellular pathways [10], among them IGF-I [4].
However, the underlying mechanism for intranasal IGF-I
uptake from the nasal cavity and its delivery to the injury
site are still unknown [11].
A strong candidate suggested for the mediation of ex-
ogenous IGF-I is the insulin-like growth factor binding
protein (IGFBP) family [12]. IGFBPs are highly con-
served among mammalian species and are essential to
IGF-I’s normal function as they are crucial regulators of
IGF-I bioavailability, transportation and localization [13].
Furthermore, IGFBPs are present in both human [14]
and rat [15] olfactory epithelia and olfactory bulb mak-
ing it a likely candidate for the uptake of IGF-I from the
nasal cavity and its transportation across the olfactory
bulb to the injury site. Studies that use des-IGF-I, an
analogue of IGF-I that has a weak affinity for IGFBPs,
show that administration of des-IGF-I into the lateral
cerebral ventricle of rats following hypoxic-ischemic in-
jury did not decrease neuronal loss, whereas IGF-I sig-
nificantly reduced neuronal loss when compared to the
vehicle treated group [16]. This suggests that IGF-I re-
quires IGFBPs to carry out its neuroprotective functions.
Among the IGFBPs present in the CNS, IGFBP-2 is es-
sential in elucidating the mechanism behind IGF-I deli-
very. Even though the overall IGFBP-2 levels decrease after
initial stages of development, it remains to be the most
abundant IGFBP in the CNS [13]. Interestingly, IGF-I has
high binding affinity for IGFBP-2, but this affinity greatly
decreases when IGFBP-2 binds to cell surface proteins
[17]. This decrease in affinity causes IGFBP-2 to release
IGF-I in close proximity of IGF-I receptors (IGF-IRs) on
the cellular surface. This interaction is thought to play a
significant role in IGF-I localization to its receptor [18]
and could also play a role in the initiation of the anti-
apoptotic signaling cascade [19].
Furthermore, high levels of IGFBP-2 mRNA have been
detected in major sites of IGF-I production in the adult
rodent brain, such as the olfactory bulb [20]. It has also
been shown that IGFBP-2 mRNA levels increase after
hypoxic-ischemic injury to the brain [21], and that IGFBP-
2 mRNA co-localizes with endogenous IGF-I at the injury
site [22,23].
Despite data suggesting a role for IGFBP-2 in endogen-
ous and exogenous IGF-I triggered neuroprotection, stu-
dies on IGFBP-2 currently have been limited to mRNA
levels and in situ hybridization, with no indication of the
actual protein levels and distribution. Therefore, the ob-
jective of this study was to determine how ischemic in-
jury may effect IGFBP-2 protein levels in the mousebrain, particularly in the stroke penumbra, the main tar-
get of neuroprotective treatments [24]. Animal studies
have shown that the effective treatment window for
stroke is 3–6 h, yet they have also shown that later time
points contribute to recovery via neurogenesis, angio-
genesis and overall tissue repair [25]. However, the ma-
jority of stroke patients do not arrive at the hospital
within the treatment window, and most clinical trials
continue with the neuroprotective treatment they are
analyzing for a few days after the initial administration
[26]. These factors make it essential to establish the dis-
tribution and concentration of any neuroprotectant and
its potential carriers past the acute phase. In the current
study we chose to explore IGFBP-2 expression and dis-
tribution in the brain in the chronic phases of stroke
[27], which would help elucidate if there is potential for
further protection/repair of the neuron population and
remodeling of the penumbra and core. Since intranasal
administration is shown to be the most effective route
for IGF-I mediated neuroprotection, we have also ana-
lyzed the olfactory epithelia and the olfactory bulb for
IGFBP-2 levels and investigated the role of IGFBPs in
transportation of intranasally administered IGF-I. Our
results indicate that IGFBP-2 and IGF-I distribution
drastically changes after hypoxic-ischemic injury and
transportation of IGF-I from the nasal cavity to the
brain is likely mediated by IGFBPs, and not the IGF-IR.
Results
IGFBP-2 in ischemic cortical neurons and astrocytes
First, we determined how ischemic conditions could affect
IGFBP-2 in vitro. Primary neuron or astrocyte cultures
were subjected to 1 h of oxygen-glucose deprivation (OGD)
followed by 24 h of re-oxygenation to mimic ischemic
stroke. The cells were then fixed and co-labeled with
IGFBP-2 and/or microtubule-associated protein 2 (MAP2)
or glial fibrillary acidic protein (GFAP) antibodies. Interest-
ingly, under control conditions, the neurons expressed a
small amount of IGFBP-2 that appeared to be only in the
cells extensions (Figure 1A). After OGD, IGFBP-2 was seen
throughout the cell body. In astrocytes under control
conditions, IGFBP-2 immunoreactivity was seen mainly
around the nucleus (Figure 1B). However, this changes
in reactive astrocytes after OGD, in which IGFBP-2 is
expressed throughout the entire cell body.
IGFBP-2 and IGF-I in mouse brain
We characterized IGFBP-2 in the olfactory bulb, cortex
and cerebellum in control mice by western blot and
ELISA (Figure 2). IGFBP-2 protein was found to be most
abundant in the olfactory bulb and was present in cortex
and cerebellum in control animals. Next, we wanted to
document the change in IGFBP-2 protein levels following






















Figure 1 IGFBP-2 in ischemic cerebrocortical neurons and
astrocytes. Primary neuron or astrocyte cultures were subjected
to 1 h of oxygen-glucose deprivation (OGD) followed by 24 h of
re-oxygenation. (A) Neurons are co-labeled with anti-MAP2 and
anti-IGFBP-2. (B) Astrocytes are co-labeled with anti-GFAP and
anti-IGFBP-2. Bar represents 10 μm.
Figure 2 IGFBP-2 protein in adult mouse brain. IGFBP-2 is
detectable in the olfactory bulb, cortex and cerebellum of adult
mice. The olfactory bulb has the highest levels of IGFBP-2 compared to
the rest of the tissue. (A) Western blot of IGFBP-2 in brain lysates.
(Rcb - recombinant protein, OB - olfactory blulb, CTX - cortex,
CB - cerebellum). (B) IGFBP-2 ELISA using brain lysates. Results are
mean ± S.D. n = 5; *p < 0.001 by ANOVA, olfactory bulb versus cortex
or cerebellum.
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sections of mice that underwent 1 h of transient middle
cerebral artery occlusion (MCAO). Images were taken of
cells in the cortex that formed the penumbra. Compared
to sham animals, both neurons and astrocytes show an in-
crease in expression of IGFBP-2 (Figure 3A, B). We did
not detect any immunoreactivity in microglia in either the
sham or MCAO groups (3C). Using an enzyme-linked im-
munosorbent assay (ELISA), we measured IGFBP-2 and
IGF-I protein levels in the stroke brain. Sham and MCAO
mice were sacrificed at 24 h or 72 h time points. The
brains were removed and stained with TTC to visualize
the penumbra. Tissue from the penumbra and stroke core
was collected as shown in Figure 4. The olfactory bulb
and cerebellum were also collected. There was no detecti-
ble difference in IGFBP-2 levels between the left and right
hemisphere of sham mice after 24 h (Figure 5A) and 72 h
(Figure 5C). IGFBP-2 levels increased after 24 h in stroke
animals compared to sham animals, but there was no sig-
nificant difference in olfactory bulb, penumbra and core
IGFBP-2 levels between the contralateral and stroke hemi-
spheres (Figure 5B). However, 72 h post-stroke, IGFBP-2
levels significantly increased in the stroke penumbra (5-
fold) and core (3-fold) when compared to the contralateral
hemisphere (Figure 5D). IGF-I levels in sham animalswere not significantly different between the left and
the right hemispheres for the brain regions analyzed.
IGF-I was not detectable in the cortex at 24 h or 72 h
(Figure 6A, C) or in the cerebellum at 72 h (Figure 6C).
IGF-I levels increased 24 h post-stroke in the penum-
bra and core, but remained highest in the olfactory
bulb (Figure 6B). Within 72 h, IGF-I levels were signifi-
cantly higher at the stroke core when compared with
contralateral hemisphere and also with the other brain
regions (Figure 6D).
Role of IGFBPs in intranasal transportation
We investigated whether IGFBPs are required for the
uptake of intranasally administered IGF-I into the CNS.
Des(1–3)IGF-I, a potent IGF-I analog [28], can bind to
the IGF-IR but cannot bind to IGFBPs [29]. We used the
selective binding capability of Des(1–3)IGF-I to identify
whether IGF-I uptake in the olfactory bulb requires IGF-
IR or IGFBPs. We hypothesized that if IGF-I uptake into
the olfactory bulb is mediated by IGF-IR, pre-incubation
with Des(1–3)IGF-I would occupy all receptor-binding
sites and significantly reduce the uptake of 125I-IGF-I into










































































Figure 3 IGFBP-2 Expression Following Hypoxic-Ischemic Injury. Brain sections of mice from either the Sham group or the MCAO group
were used to visualize IGFBP-2 in neurons, astrocytes and microglia. All images were taken of cells in the cortex that formed the penumbra.
(A, B) Neurons are co-labeled with anti-NeuN and anti-IGFBP-2. (C) Astrocytes are co-labeled with anti-GFAP and anti-IGFBP-2. (D) Microglia are
co-labeled with anti-Iba-1 and anti-IGFBP-2. Bars represent 20 μm.
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into the brain (Figure 7). Also, pre-incubation with 125I-
IGF-I and immediate application of a molar excess of Des
(1–3)IGF-I did not affect 125I-IGF-I uptake into the brain.
However, pre-incubation with unlabeled IGF-I was cap-
able of outcompeting 125I-IGF-I, in presence and absence
of Des(1–3)IGF-I.Discussion
IGFBP-2 & IGF-I protein levels in mouse brain
The 5-fold increase of the IGFBP-2 protein levels in the
penumbra has two implications. It confirms the previous
mRNA data and further demonstrates that the increase
changes the distribution pattern of IGFBP-2 in control
vs. stroke conditions (Figure 5). This region specific
Figure 4 Visualization of the stroke core and penumbra. The stroke core is defined as the areas where perfusion is completely absent during
occlusion, resulting in dead tissue. The stroke penumbra on the other hand receives limited perfusion during occlusion and still contains viable
cells that are the main target of neuroprotectants. The drawing (left) shows how tissue collection was carried out. The squares on the drawing
indicate the areas for penumbra collections (which correspond to the pink rim outlined in blue in the TTC image); the area inside the squares is
the area used for stroke core collections (corresponding to the white area in the TTC image).
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as increased levels of IGFBP-2 in untreated animals in the
penumbra indicates a possible neuroprotective role for en-
dogenous IGFBP-2. This role is most likely associated with
its regulation of IGF-I, and we show that IGF-I distribution
in the brain changes in a pattern similar to IGFBP-2.
IGF-I mRNA expression is detectable in many brain re-
gions during embryogenesis, such as the spinal cord,Figure 5 IGFBP-2 protein levels following hypoxic-lschemic injury. IGF
left and the right hemispheres for the brain regions analyzed (A, C). For th
between the contralateral and stroke hemispheres 24 h post-stroke (B). IGF
penumbra (5-fold) and core (3-fold) when compared to the contralateral h
region, IGFBP-2 levels of the two hemispheres were compared. (*) on the g
a significant difference between the stroke and the contralateral hemisphe
hemisphere vs. stroke hemisphere.midbrain, cerebral cortex, hippocampus, and olfactory
bulb [13]. However, IGF-I transcription decreases sig-
nificantly postnatally and reaches very low levels in the
adult [30,31], with the exception of the olfactory bulb,
where IGF-I expression persists at a high level throughout
life [32]. We show that initially IGF-I is highly expressed
in the olfactory bulb but is not detectable in other brain
regions; however, within 72 h post-stroke it becomesBP-2 levels of sham animals are not significantly different between the
e brain regions analyzed, IGFBP-2 levels are not significantly different
BP-2 levels on the stroke hemisphere increase significantly (*) in the
emisphere 72 h post-stroke (D). For statistical analysis, for each brain
raphs denotes the brain regions where the statistical analysis revealed
re. Results are mean ± S.D. n = 5; *p < 0.05 by ANOVA contralateral
Figure 6 IGF-I Levels Following Hypoxic-Ischemic Injury. IGF-I levels of sham animals are not significantly different between the left and the
right hemispheres for the brain regions analyzed (A, C). IGF-I is detectable in the olfactory bulb, but not the cortex (24 h, 72 h) and cerebellum
(72 h) of the sham animals (A, C). IGF-I levels are highest in the olfactory bulb and detectable in the penumbra and core 24 h post-stroke (B).
At 72 h IGF-I levels are significantly higher in the core region (†) when compared to the other brain regions (D). For statistical analysis, for each
brain region, IGF-I levels of the two hemispheres were compared. (*) on the graphs denotes the brain regions where the statistical analysis revealed a
significant difference between the stroke and the contralateral hemisphere. Results are mean ± S.D. n = 5; *p < 0.05 by ANOVA contralateral hemisphere
vs. stroke hemisphere and †p < 0.05 by ANOVA core versus olfactory bulb, penumbra, cerebellum.
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(Figure 6). Such an increase in IGF-I levels in the stroke
penumbra further supports the hypothesis that IGF-I is
an integral part of the brain’s endogenous response to
hypoxic-ischemic brain injury [33] and that IGFBP-2
also has a function in this response. Another region spe-
cific change of protein levels occurs in the stroke core
where a significant increase of IGF-I and IGFBP-2 levels
is observed. This might be due to IGFBP-2 being freed
from its cell surface interactions with the necrotic cells.
Even though the neurons in the stroke core are less
likely to benefit from IGF-I, it might also be used to cre-
ate a pool for IGF-I. Such a pool would be especially
beneficial to the cells that are positioned in proximity to
the necrotic (stroke core) border of the penumbra as it
would provide these cells with a source for the neuro-
protective factor IGF-I. Here, IGF-I can exert neuropro-
tection by initiating the Akt pathway and preventing
neuronal apoptosis [34].
Role of IGFBPs in intranasal transport
In order to investigate the role of IGFBPs in the uptake
of IGF-I from intranasal cavity into the CNS, we used
the selective binding capability of Des (1–3)IGF-I [29].We hypothesized that if IGF-I uptake into the olfactory
bulb is mediated by IGF-IR, pre-incubation or co-
incubation with Des (1–3)IGF-I would compete for and
occupy all the receptor-binding sites and significantly re-
duce the uptake of 125I-IGF-I (labeled IGF-I) into the
brain. Our results indicate that such competition for the
receptor does not affect labeled IGF-I uptake, entailing
that IGF-I uptake is facilitated by another mechanism.
This hypothesis is further supported by our finding that
pre-incubation with unlabeled IGF-I, which binds to
IGFBPs and IGF-IR, significantly reduced labeled IGF-I
in the brain (Figure 7). Taken together, the results sug-
gest the uptake of intranasal IGF-I is not receptor me-
diated and is most likely facilitated by IGFBPs. The
significance of this finding is its potential link to drug
delivery methods. Currently the prominent method is
the systemic administration which relies on the unpre-
dictable and unreliable permeabilization of the BBB [7].
However, relying on the breakdown of the BBB for ac-
cess to the brain tissue is highly variable [35]. There-
fore, exploration of alternative delivery methods, such
as those involving binding protein mediated routes,










Control 125I-IGF-I IGF-I IGF-I Des(1-3) 125I-IGF-I
- - 125I-IGF-I Des(1-3) 125I-IGF-I Des(1-3)
- - - 125I-IGF-I - -
Preincubation
Figure 7 Uptake of IGF-I is not mediated by IGF-IR. Pre-incubation with a molar excess of Des(1–3)IGF-I (100 ng/ml), which does not bind to
IGFBPs, does not block the uptake of 125I-IGF-I (20 ng/ml) into the brain. Pre-incubation with unlabeled IGF-I (20 ng/ml), which binds both to
IGF-IR and IGFBPs, blocks 125I-IGF-I (20 ng/ml) uptake into the brain (*). Results are mean ± S.D. n = 6; *p < 0.05 by ANOVA 125I-IGF-I versus
IGF-I + 125I-IGF-I and IGF-I + Des(1–3)IGF-I + 125I-IGF-I.
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long term recovery
IGFBP-2 has been widely studied in cancer research, where
it was shown to be both inhibiting and stimulating for IGF-
I linked tumor growth [36]. In the interpretation of IGFBPs
role in hypoxic-ischemic injury a duality similar to the one
observed in cancer research exists. There are several studies
that demonstrated that IGFBPs antagonize IGF-I and limit
its neuroprotective potential [37]. However, there are also
studies that documented that IGFBP binding is essential for
the IGF-I mediated neuroprotection [16]. Even though
IGFBP-2 binding to IGF-I decreases IGF-I bioavailability,
it also increases IGF-I half-life. This could be especially
important if part of the brain’s endogenous response to
hypoxic-ischemic injury involves transportation of IGF-I
from other regions. The possibility for transportation is
supported by our finding that IGFBP-2 and IGF-I distribu-
tion changes after stroke. While their levels are still high
in the olfactory bulb, they become more abundant at the
injury site. Whether this is due to local upregulation or
transportation, presence of IGFBP-2 at the penumbra in
itself is noteworthy. As described before [24] damage due
to stroke is not uniform across the cortex. Stroke core can
be defined as the areas where perfusion is completely ab-
sent during occlusion, resulting in necrotic tissue. Stroke
penumbra, on the other hand, receives limited perfusion
during occlusion. Cells in the penumbra have the potential
to survive if treated, which in turn might improve theneurological and behavioral outcome post-stroke. There-
fore, treatment studies utilizing IGF-I should focus on de-
livering the neuroprotectant to the stroke penumbra. It is
at this point that IGFBP-2 might take the center stage by
binding to IGF-I at the point of delivery or endogenous
expression, protecting it from degradation, facilitating its
transportation to the injury site and finally delivering IGF-
I to its target. Furthermore, dominance of IGFBP-2 as the
most abundant IGFBP in the olfactory bulb and its pres-
ence in the olfactory epithelia qualifies IGFBP-2 as a can-
didate for facilitating this uptake. This is supported by our
finding that intranasally administered IGF-I most likely
uses a currently uncharacterized IGFBP-mediated trans-
port system to reach the brain. This also indicates that
a similar pathway/system might exist for endogenous
IGF-I transportation to the injury site as an endogenous
response to brain injury.
Since our time points include the chronic phases of
stroke, it is imperative to discuss the impact of the IGF
system on the late remodeling of the injury site and sur-
rounding tissue. We know from both human and animal
studies [38,39], neuroprotective therapies for stroke are
most effective within a 3–6 h time window after the ini-
tial insult [33] and that by 72 h, the size of the core sta-
bilizes. Even if the IGF system still functions to stabilize
the penumbra and delay and/or prevent neuronal death
up to 24–48 h, there must be alternative explanations
for their continuous upregulation up to 72 h after stroke.
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cular remodeling and neuroplasticity in penumbra and
core at later time points [40,41]. We suggest that IGFBP-2
might also have an IGF-I dependent and independent role
in such structural changes that occur in the chronic
phases. This explanation would also support in situ
hybridization studies where IGFBP-2 is found to localize
with activated astrocytes and microglia [23,42]. Even
though astrocyte and microglia proliferation, resulting
in glial scarring, is known to be detrimental to neuronal
survival, these cell types are also known to be associated
with post-stroke angiogenesis and neurogenesis via ex-
pression of other proteins [43]. Hence their pro and
anti-recovery roles need to be in balance [44]. IGF-I
(neuroprotection) and IGFBP-2 (IGF-I regulation, angio-
genesis, neurogenesis) might play a role in restoring such
balance. Since tissue remodeling is a long term process
[45], lasting increase in IGFBP-2 protein levels might be
related to recovery mechanisms employed by various cell
types in the CNS.
In the current paper we have provided data that intrana-
sal IGF-I uptake is not IGF-IR mediated and showed that
IGFBP-2 is present in the olfactory tissue, making it a
likely candidate for transporting the intranasally adminis-
tered IGF-I into the brain. However, no direct link has
been established for IGFBP-2′s transport function of IGF-
I into the stroke penumbra. Therefore, further competi-
tion experiments designed specifically towards IGFBP-2
are required to clarify IGFBP-2′s role. Similarly, IGF-I in-
dependent role of IGFBP-2 after stroke, needs to be fur-
ther investigated using IGFBP-2 inhibition experiments.
Such studies will clarify the acute function of IGFBP-2 in
neuroprotection and also its long-term role in tissue re-
covery following a stroke event.
Conclusions
The current results and the previous studies strongly
suggest IGFBP-2′s role in hypoxic-ischemic injury needs
to be explored further [46]. IGF-I is a promising neuro-
protectant considered to be beneficial for not only stroke
but a diverse array of neurological diseases such Amyo-
trophic Lateral Sclerosis (ALS) and traumatic brain in-
jury [47,48]. Therefore, any insight into its mediation
will allow us to take advantage of the brain’s existing
neuroprotective and remodeling mechanisms. Establish-
ing these mechanisms will in turn result in more effect-
ive treatments that incorporate improved administration
methods and better dose regulation.
Methods
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of The Univer-
sity of Texas Health Science Center San Antonio and
adhered to the National Institute of Health Guidelines.Cell culture
Primary cortical neurons and astrocytes were isolated
from 17 day-old Sprague–Dawley rat embryos as de-
scribed previously [49,50]. Briefly, the cerebral cortices
were isolated and the meninges removed. The cortices
were chopped into small pieces and then digested with
trypsin-EDTA (0.125%) for 30 min at 37°C. The digested
cells were mechanically dissociated by titration, filtered
through a 40 μm cell strainer and collected by centrifu-
gation (700 g, 2 min). For pure neuronal cultures, cells
were re-suspended in serum-free Neurobasal Medium
supplemented with B27, and plated at 5 × 105 cells/cm2
onto poly-L-lysine coated glass coverslips. Cells were
maintained at 37°C, 5% CO2, in a humidified environ-
ment, and allowed to mature for 17 days in vitro (DIV)
[34]. For pure astrocyte cultures, cells were re-suspended
in DMEM containing 10% fetal bovine serum, plated at
7,500 cells/cm2 onto tissue culture treated flasks and
maintained at 37°C, 5% CO2 in a humidified environ-
ment until confluent (~14 DIV). Then, astrocytes were
shaken overnight at 350 rpm to remove microglial cells
and plated onto glass coverslips. The purity of each cul-
ture was tested using immunofluorescent techniques.
Cells were labeled with a neuronal marker (microtubule
associated protein 2 (MAP2), Sigma, M9942) and an
astrocyte marker (glial fibrillary acidic protein (GFAP),
Sigma, G6171). Neuronal cultures contained less than
3% GFAP-positive cells and astrocyte cultures did not
contain any MAP2-positive cells.
Oxygen–glucose deprivation and immunocytochemistry
The culture medium was replaced by a glucose-free
Neurobasal-A media (Invitrogen), which was previously
saturated with 1% O2. The cultures were then placed in
an airtight incubation chamber (CBS Scientific) and
flushed with a continuous influx of 1% O2 at a flow rate
of 20 L/minute. The chamber was then sealed to main-
tain the gas composition and placed into an incubator at
37°C for 60 minutes. Afterwards the cultures were re-
moved from the airtight hypoxic chamber and the
glucose-free media was replaced with the pre-OGD con-
ditioned medium. The cells were then maintained in
normoxic conditions at 37°C for 24 h. Control cell cul-
tures were not exposed to OGD. Cells were then rinsed
in phosphate buffered saline (PBS), fixed in 4% parafor-
maldehyde for 10 minutes, and permeabilized with 0.5%
Triton-X/PBS for 10 minutes. After blocking for 1 h at
room temperature, the cells were incubated in primary
antibodies (IGFBP-2, R&D Systems, AF797; MAP2, Sigma,
M9942; GFAP, Sigma, G6171) and secondary antibodies
(Alexa Fluors, 1:1000, Invitrogen) in blocking buffer. Cover-
slips were mounted onto slides with ProLong Gold Media
(Invitrogen) and visualized with Zeiss AxioImage Olympus
FV-1000 confocal microscope (Olympus America Inc.) and
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pus America Inc.). We used an n = 3 for each experi-
mental group.Transient middle cerebral artery occlusion (MCAO)
Adult male C57BL/6 mice weighing 20–25 g were anesthe-
tized with 1.5-2% isoflurane. The animal’s body temperature
was maintained at 37°C with a heating blanket and feed-
back system (Harvard Apparatus). Transient focal cerebral
ischemia was induced by occlusion of the left MCA using
the intraluminal filament model [51]. Reperfusion was per-
formed by withdrawal of the filament 1 h after occlusion.
Surface cerebral blood flow was monitored during MCAO
by a laser doppler flowmeter (Perimed). Mice with re-
maining surface cerebral blood flow more than 20% of
baseline were deemed to have unsuccessful MCAOs and
were excluded from the experiment. Sham animals were
subjected to the same surgical procedure as the stroke
animals minus the occlusion of the MCA.Immunohistochemistry
Mice were transcardially perfused with normal saline
followed by 4% paraformaldehyde 24 h post-stroke. Brains
were harvested and immediately frozen in liquid nitrogen
cooled isopentane. Coronal sections (25 μm) were cut with
a crysostat (Leica) and fixed with acetone (10 m, -20°C).
Sections were then permeabilized (0.1% Triton-X/PBS,
5 m, RT), blocked (5% Bovine Serum Albumin/PBS,
1.5 h, RT) and incubated in primary (IGFBP-2, R&D
Systems, AF797; Neuronal Nuclei (NeuN), Millipore,
MAB377; GFAP, Sigma, G6171; Iba-1, Wako, 019–
19741) and secondary antibodies (Alexa Fluors, 1:500,
Invitrogen) in blocking buffer. Coverslips were mounted
onto slides with ProLong Gold Media (Invitrogen) and
visualized with Zeiss AxioImage Olympus FV-1000
confocal microscope (Olympus America Inc.) and im-
ages captured with FluoView v. 5.0 software (Olympus
America Inc.). We used an n = 3 for each experimental
group.Tissue collection
Animals were perfused with saline solution. Olfactory
epithelia, olfactory bulb, cortex (penumbra and core for
the stroke group) and cerebellum were harvested using a
dissecting microscope. In order to aid the collection of
penumbra and core, 2 mm sections (Bregma +1 to −1)
were stained with 2% 2,3,5-triphenyl tetrazolium chlo-
ride (TTC). Samples were sonicated (15%, 15 seconds)
in lysis buffer (Cell Signaling) and centrifuged (14,000 rpm,
10 m, 4°C). Protein concentration of the supernatant was
determined using bicinchoninic acid protein assay (Pierce).
We used an n = 5 for each experimental group.Enzyme-linked immunosorbent assay (ELISA)
ELISA development kits (R&D Systems) were used to
quantify IGF-I and IGFBP-2 levels in brain tissue, ac-
cording to the manufacturer’s guidelines. A 96-well mi-
croplate was coated with the monoclonal capture
antibody specific for IGFBP-2 (R&D Systems, MAB7971)
or IGF-I (R&D Systems, MAB791). Wells were then in-
cubated in blocking buffer, tissue homogenates (7.5 μg/
well), standards, appropriate detection antibody (IGFBP-2
biotinylated antibody, R&D Systems, BAF797; IGF-I biotiny-
lated antibody, R&D Systems, BAF791), and streptavidin-
Horseradish Peroxidase (HRP) (Pierce). Following the
streptavidin-HRP incubation, wells were covered with tet-
ramethylbenzidine (TMB) substrate (Cell Signaling), and
the HRP/TMB reaction was terminated with STOP So-
lution (Cell Signaling). The optical density was read at
450 nm using a spectrophotometer (Beckman Coulter
Inc). Standard curves were used to interpolate the IGF-I
and IGFBP-2 levels of the samples. Tissue homogenates
were run in triplicates. We used an n = 5 for each ex-
perimental group.
Intranasal administration
Des(1–3)IGF-I (GroPep) was diluted in 0.25% human al-
bumin, 5.8 mg/ml sodium citrate, 5.8 mg/ml NaCl and
0.06 mg/ml citric acid. IGF-I and 125I-IGF-I were dis-
solved in 10 mM sodium succinate buffer and 140 mM
NaCl (pH 6.2). A recently described method [3] for
intranasal application was used. Treatment solutions
were applied dropwise (2 μl/drop) to control mice over
12 m, alternating between each nare. The mouth and
the alternate nare were closed during application to
allow complete inhalation of the solution into the nasal
cavity. Treatment solution incubation time was 20 m.
Scintillation measurement
Whole brains (without the olfactory bulb) from mice were
collected 20 minutes after the application of cytokines and
homogenized in 1 ml buffer (50 mM Tris–HCl, pH 7.4)
and mixed with 2 ml Microscint liquid scintillation cocktail
(PerkinElmer) in a scintillation glass vial and measured in
presence of I-125 Pico-Calibrator, #5080125, (PerkinElmer)
in Topcount scintillation counter (PerkinElmer). We used
an n = 6 for each experimental group.
Data analysis
ELISA data was analyzed using Prism software (Graph-
pad). Graphs presented in the paper show mean and S.
D. for n = 5 and the significance analysis. IGF-I and
IGFBP-2 levels were analyzed by one-way analysis of
variance (ANOVA, p < 0.05 was taken as statistically sig-
nificant) followed by Tukey’s Multiple Comparison test.
For scintillation data, differences in dpm levels were
analyzed by one-way ANOVA (p < 0.05 was taken as
Fletcher et al. BMC Neuroscience 2013, 14:158 Page 10 of 11
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IGF-I and IGF-I + Des(1–3)IGF-I + 125I-IGF-I. Results are
shows as mean ± S.D.
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